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OBJECTIVE—Obesity alters gut microbiota ecology and asso-
ciates with low-grade inﬂammation in humans. Roux-en-Y gastric
bypass (RYGB) surgery is one of the most efﬁcient procedures
for the treatment of morbid obesity resulting in drastic weight
loss and improvement of metabolic and inﬂammatory status. We
analyzed the impact of RYGB on the modiﬁcations of gut
microbiota and examined links with adaptations associated with
this procedure.
RESEARCH DESIGN AND METHODS—Gut microbiota was
proﬁled from fecal samples by real-time quantitative PCR in 13
lean control subjects and in 30 obese individuals (with seven type
2 diabetics) explored before (M0), 3 months (M3), and 6 months
(M6) after RYGB.
RESULTS—Four major ﬁndings are highlighted: 1) Bacteroides/
Prevotella group was lower in obese subjects than in control
subjects at M0 and increased at M3. It was negatively correlated
with corpulence, but the correlation depended highly on caloric
intake; 2) Escherichia coli species increased at M3 and inversely
correlated with fat mass and leptin levels independently of
changes in food intake; 3) lactic acid bacteria including Lacto-
bacillus/Leuconostoc/Pediococcus group and Biﬁdobacterium
genus decreased at M3; and 4) Faecalibacterium prausnitzii
species was lower in subjects with diabetes and associated
negatively with inﬂammatory markers at M0 and throughout the
follow-up after surgery independently of changes in food intake.
CONCLUSIONS—These results suggest that components of the
dominant gut microbiota rapidly adapt in a starvation-like situa-
tion induced by RYGB while the F. prausnitzii species is directly
linked to the reduction in low-grade inﬂammation state in obesity
and diabetes independently of calorie intake. Diabetes 59:
3049–3057, 2010
O
besity is characterized by increased fat mass
accumulation and the development of comor-
bidities including other metabolic and cardio-
vascular diseases. Even though some but not
all environmental factors have been elucidated, the in-
creasing epidemic of obesity appears virtually impossible
to control, and the mechanisms associated with fat mass
expansion need to be identiﬁed. Obesity is considered a
low-grade inﬂammatory disease with adipose tissue con-
tributing to this state via the secretion of molecules
capable of altering metabolic homeostasis (1,2). A novel
factor identiﬁed to play a role in human obesity and
associated metabolic risks is the commensal microbiota of
the intestine (3).
A role for the intestinal microbiota in harvesting energy
from food (4) and regulating body fat storage (5) was
proposed in rodents. Germ-free mice colonized by micro-
biota increase their body fat and develop insulin resistance
in spite of a 30% decrease in food intake. These changes
were associated with a dysbiosis in obese mice: an in-
creased representation of the Firmicutes phylum and a
reduced representation of the Bacteroidetes phylum (6).
Other studies suggested a contribution of the gut micro-
biota-produced lipopolysaccharides to inﬂammation and
development of metabolic syndrome (7–9). In humans,
increased endotoxemia (circulating lipopolysaccharides)
was found to be associated with increased fat consump-
tion (10). In obese patients losing weight throughout low
calorie diets, diminished Bacteroidetes and increased Fir-
micutes were found trended to that of lean control sub-
jects at the end of the dietary intervention (11). However,
modiﬁcation of the Firmicutes-to-Bacteroidetes ratio ob-
served in obese individuals was not conﬁrmed in other
studies (12). No study has clearly explored the association
between these bacterial changes and improvement of
metabolic or inﬂammatory phenotypes associated with
weight modiﬁcation over time.
Roux-en-Y gastric bypass (RYGB) surgery is an increas-
ingly effective model to study in this context. RYGB leads
to major improvements in metabolic and inﬂammatory
markers (13). This procedure allows for an understanding
of the molecular adaptations underlying the observed
health beneﬁts and the potential role of calorie restriction
in changes in gut microbiota pattern.
Our present work analyzed the microbiota proﬁles in the
feces of morbidly obese subjects before and after RYGB.
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changes and a range of body composition, metabolic, and
inﬂammatory markers. These results provide new insight
regarding gut microbiota changes in obese subjects after
RYGB and highlight some bacterial groups as possible
factors associated with changes in nutritional status and
others with metabolic and inﬂammatory parameters.
RESEARCH DESIGN AND METHODS
Thirty obese subjects (27 women and 3 men) enrolled in a bariatric surgery
program were recruited at the Center of Reference for Medical and Surgical
Care of Obesity (Pitie ´-Salpe ˆtrie `re Hospital, Paris, France). The patients had
the criteria for obesity surgery: BMI 40 kg/m
2 with at least two comorbidities
(hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea
syndrome). The subjects’ weight was stable ( 2 kg) for at least 3 months
prior to surgery. Subjects were exempted from acute or chronic inﬂammatory
diseases, infectious diseases, viral infection, cancer, and/or known alcohol
consumption. No antibiotics were taken before surgery or during the postsur-
gery follow-ups. Clinical and biological parameters were assessed prior to
RYGB surgery (i.e., basal or M0) and at 3- and 6-months postsurgery (M3 and
M6, respectively). The oral glucose tolerance test was performed in the 23
nondiabetic subjects (OB/nD subgroup). All had a glycemia 11 mmol/l 2 h
after 75-g oral glucose. Seven subjects had type 2 diabetes (OB/D subgroup)
with a fasting glycemia over 7 mmol/l and/or the use of an antidiabetic drug.
Two individuals necessitated insulin therapy while the other ﬁve subjects
were treated with metformin and hypolipidemic drugs (either ﬁbrate or
statins). Thirteen normal weight, healthy women volunteers living in the same
area as the obese subjects were recruited as a lean control subject group. The
Ethics Committee of the Ho ˆtel-Dieu Hospital approved the clinical protocol.
All subjects gave written informed consent.
Dietary assessment. At each visit, caloric intake and macronutrient portions
were evaluated by a registered dietitian during a 1-h questioning period.
Multivitamins and iron supplements were provided to avoid deﬁciencies, a
well-known secondary effect of bariatric surgery (14). Serum iron, ferritin, the
coefﬁcient of saturation of iron in transferrin, vitamins (A, D, E, B1, B12, and
B9), micronutrients, and calcium were measured using routine bio-clinical
tests. Serum analyses showed that these parameters were in the normal range
at all time points (data not shown).
Body composition, metabolic, and inﬂammatory parameters. Body com-
position was determined before and after the surgery by dual-energy X-ray
absorptiometry (GE Lunar Prodigy Corporation, Madison, WI), and resting
energy expenditure was measured by indirect calorimetry (Deltatrac, Datex,
France). Periumbilical surgical biopsies of subcutaneous adipose tissues were
obtained and adipocyte diameter was measured as described (15). Blood
samples were obtained at each time point after 12-h fasting to measure plasma
lipids (total cholesterol, HDL cholesterol, and triglycerides), insulin, glucose,
leptin, adiponectin, and inﬂammatory markers (high-sensitivity C-reactive
protein [hs-CRP], interleukin [IL]-6, orosomucoid).
Fecal samples. Fecal samples were obtained in the morning before breakfast.
Whole stools were self-collected in sterile boxes and stored at 20°C within
4 h. Samples were treated in the laboratory as 200-mg aliquots and stored at
80°C until further analysis. The 30 obese subjects and 13 healthy control
subjects delivered samples at M0. During follow-ups, fecal samples were
obtained for 26 subjects (including 6 diabetic subjects) at M3 and for 15
subjects (including 5 diabetic subjects) at M6. A complete course of stool
samples (M0, M3, and M6) was ﬁnally obtained for 10 individuals.
DNA extraction from fecal samples. DNA was extracted from (200-mg
aliquots) feces as previously described (16). After the ﬁnal precipitation, DNA
was resuspended in 150 ml of TE buffer and stored at 20°C prior to further
analysis.
Oligonucleotide primers and probes. The primers and probes used in this
study are presented in supplementary Table 6, available in an online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0253/DC1. TaqMan
qPCR was adapted to quantify the total bacteria population in addition to the
dominant (1% of fecal bacteria) bacterial species Clostridium leptum (C.
leptum), Clostridium coccoides (C. coccoides), Bacteroides/Prevotella, and Bi-
ﬁdobacterium. Real-time qPCR using SYBR Green was performed for the
Lactobacillus/Leuconostoc/Pediococcus and for the subdominant bacterial spe-
cies Escherichia coli (E. coli), as well as for the Faecalibacterium prausnitzii
(F. prausnitzii). The TaqMan probes were synthesized by Applied Biosystems
Applera-France (Courtaboeuf, France). Primers were purchased from MWG
(MWG-Biotech AG, Ebersberg, Germany).
Real-time qPCR. Real-time qPCR was performed using an ABI 7000 Sequence
Detection System with software version 1.2.3 (Applied Biosystems, Foster
City, CA). Ampliﬁcation and detection were carried out in 96-well plates with
TaqMan Universal PCR 2 MasterMix (Applied Biosystems) or with SYBR
Green PCR 2 Master Mix (Applied Biosystems). Each reaction was run in
duplicate in a ﬁnal volume of 25 ml with 0.2 mmol/l ﬁnal concentration of each
primer, 0.25 mmol/l ﬁnal concentration of each probe, and 10 l of appropri-
ately diluted DNA samples. Ampliﬁcations were carried out using the follow-
ing ramping proﬁle: one cycle at 95°C for 10 min, followed by 40 cycles of 95°C
for 30 s, 60°C for 1 min. For SYBR Green ampliﬁcations, a melting step was
added to improve ampliﬁcation speciﬁcity. The total numbers of bacteria were
inferred from averaged standard curves as described (17).
Normalization of qPCR data. All bacteria results were presented as the
mean of the log10 value  SEM. To recount for water content in fecal samples,
data for each fecal sample was normalized as previously described (16). The
level for each bacterial species or group was subtracted from all bacteria
content. The data are presented as log number of bacteria per gram of stool.
Day-to-day variations. To evaluate the stability of results of microbiota, we
added a supplementary experiment to estimate day-to-day variations of fecal
samples. Five healthy lean women (BMI: 23  1; age 28 years  0.3) were
included in this study. Fecal samples were collected during two consecutive
days in the same conditions and with the same method of collection and
treatment as cited above (supplementary Table 5).
Biochemical assays. Plasma glucose was measured by the glucose oxidase
method (Beckman Fullerton, Palo Alto, CA). Plasma insulin was determined
by using the reactive kit from Abbott (Rungis, France). Plasma triglycerides
and free fatty acids were measured with Biome ´rieux kits (Marcy l’Etoile,
France), and total cholesterol, HDL cholesterol, and LDL cholesterol with
Labintest kits (Aix-en-Provence, France). Leptin, adiponectin, hs-CRP, IL-6,
and TNF- were determined by using ELISA kits from R&D Systems (Minne-
apolis, MN).
Statistical analysis. All values are expressed as mean  SEM. Homeostasis
model assessment of insulin resistance (HOMA-IR), insulin sensitivity (HOMA-
S%), and -cell function (HOMA-B%) provided in supplementary Table 2 were
estimated. The composition of microbiota is expressed as mean of the log10 of
the normalized PCR values. Wilcoxon rank sum tests were used to assess
statistical signiﬁcance of differences between lean control subjects and OB/nD
and OB/D subjects at baseline. Paired Wilcoxon tests were performed to
analyze changes in these parameters between various time points after
surgery.
Principal component analysis (PCA) combined with co-inertia analysis was
used to explore complex and potentially redundant relationships involving a
relatively large number of clinical, biological, and microbiological variables at
baseline and following RYGB. Co-inertia analysis is a coupling method for
comparing different types of parameters presenting different variances. The
signiﬁcances of the associated variations of biological and clinical parameters
and of bacterial counts during the follow-up after surgery were evaluated by
Monte Carlo tests. Signiﬁcant associations were visualized by a circle of
correlations while their intensity was expressed by computing Spearman
correlation coefﬁcients (Rs).
The signiﬁcances of the strongest dynamic associations of clinical-biolog-
ical parameters and of bacterial counts after surgery among those identiﬁed
by PCA and co-inertia analysis were further evaluated by building linear
mixed-effects (LME) models to test for inter-variable redundancies and to
adjust for potential confounding factors. All LME models were ﬁt by maxi-
mizing the restricted log-likelihood (REML) of their estimated coefﬁcients. All
statistical analyses were performed using the R software (http://www.r-
project.org). PCA and co-inertia analyses were performed with ADE-4 pack-
age (18). LME modeling was performed by relying on statistical functions
available in the nlme package (19). All statistical computations were consid-
ered signiﬁcant when resulting P values were 0.05 threshold.
RESULTS
Clinical and biological characteristics before RYGB.
The clinical characteristics of lean and OB/D or OB/nD
subjects are presented in supplemental Table 1. While
mean age between control subjects and OB/nD subjects
were not statistically different, OB/D subjects were older.
RYGB improves markedly clinical, metabolic, and
inﬂammatory phenotypes. Along with the drastic reduc-
tion in food consumption, RYGB resulted in signiﬁcant
changes in body weight and fat mass from M0 to M3 and
M6 (Table 1). For the majority of parameters, improve-
ments occurred rapidly in the ﬁrst 3 months. At M6, the
subjects had lost 22% of their initial weight (P  0.01). Fat
mass decreased and the percentage of fat-free mass in-
creased. These changes were associated with a decrease
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concentrations (P  0.01). These improvements were
observed in both groups (OB/nD and OB/D) when consid-
ered separately (supplementary Table 2). However, the
improvements found in inﬂammatory parameters (hs-CRP,
orosomucoid) in the whole group of obese subjects (Table
1) disappeared when considered separately (supplemen-
tary Table 2). A slight decrease in orosomucoid remained
in the OB/nD group.
Plasma glucose, insulin levels, glycosylated hemoglobin
(A1C) and HOMA-IR decreased signiﬁcantly post-RYGB,
however adiponectin concentration did not change signif-
icantly at M3 (Table 1). An improvement in insulin sensi-
tivity (HOMA-S%) of the OB/nD group and an amelioration
of blood glucose homeostasis were found in the seven
diabetic subjects (supplementary Table 2). Antidiabetic
drugs were stopped in diabetic subjects as well as hypo-
lipidemic treatment in all obese individuals.
Basal bacterial groups counts: decreased amount of
Bacteroides/Prevotella in obesity and of F. prausnit-
zii in diabetes. Average counts for each bacterial group
of control, OB/nD, and OB/D subjects are presented in
Table 2 and Fig. 1. The Bacteroides/Prevotella group was
lower in obese subjects (OB/nD: P 	 0.039 and OB/D: P 	
0.038) compared with lean subjects. However, while the
population of C. leptum tended to be lower in obese
subjects, the differences did not reach statistical signiﬁ-
cance probably due to the high interindividual variability
in this bacterial population subgroup. F. prausnitzii spe-
cies qPCR system could reliably distinguish between the
control and OB/D microbiota. Their counts in the OB/D
microbiota were signiﬁcantly lower when compared with
those of the control group (P  0.01) and OB/nD subjects
(P  0.05). These results suggest that while obesity leads
to modiﬁcation in the Bacteroides/Prevotella group, diabe-
tes seems to inﬂuence the abundance of F. prausnitzii
(supplementary Fig. 1).
Bacterial changes after RYGB: increased amount of
Bacteroides/Prevotella and E. coli, decreased Bi-
ﬁdobacterium and Lactobacillus/Leuconostoc/Pe-
diococcus groups. Changes of bacteria amounts were
observed in the obese group (OB/nD and OB/D together)
after surgery but with a different pattern depending on the
bacterial group (Fig. 1). Supplementary Table 3 illustrates
the progression of all bacterial populations within the
microbiota before (M0) and after RYGB (M3 and M6) in
each obese group and separated by the diabetic status. In
the OB/D subjects, a similar pattern of changes as the one
characterizing the OB/nD subjects was observed, but
changes for certain bacterial groups did not reach statis-
tical signiﬁcance. The Bacteroides/Prevotella population,
whose level was lower in obese subjects before RYGB,
increased at M3 and remained stable until M6 (Fig. 1) at a
level close to that of the control subjects. Importantly, the
obese subjects remained obese at M6 (BMI 37.1  1.3 vs.
21.1  0.4, obese and lean subjects, respectively). At M3,
E. coli showed a rapid and signiﬁcant increase reaching a
level higher than that of the control subjects. An opposite
pattern was observed for both the Biﬁdobacterium and
Lactobacillus/Leuconostoc/Pediococcus groups. Levels of
both populations decreased at M3 and M6 and reached, in
the case of Biﬁdobacterium, a level lower than that
measured in the control subjects.
Interestingly, the level of F. prausnitzii, which was
TABLE 1
Clinical and biological characteristics of obese subjects before, and 3 and 6 months after gastric surgery
After bypass
Before bypass 3 months 6 months
Food intake
Food intake (kcal) 1,933  101
A 1,080  87
B 1,355  54
C
Adiposity markers
Body weight (kg) 126  4.2
A 107  3.9
B 98  3.8
C
BMI (kg/m
2) 47.6  1.5
A 40.6  1.3
B 37.1  1.3
C
Adipocyte diameter (m) 116.7  1.5
A 110.7  1.0
B 103.3  3.2
C
REE (kcal) 1,814.4  54.8
A 1,842.5  53.6
A 1,551.1  42.9
B
Fat mass % 47.9  1.0
A 44.5  1.0
B 41.3  1.2
C
Fat-free mass % 50.0  1.0
A 53.0  0.9
B 55.9  1.1
C
Leptin (ng/ml) 50.8  3.7
A 25.6  2.5
B 24.9  2.8
B
Plasma glucose homeostasis and
insulin sensitivity
Glycemia (mmol/l) 6.4  0.5
A 5.1  0.2
B 4.8  0.1
B
A1C (%) 6.4  0.3
A 5.7  0.1
B 5.8  0.1
B
Insulinemia (U/ml) 17.1  1.6
A 10.7  0.9
B 6.9  0.7
C
HOMA-IR 0.88  0.09
A 0.63  0.03
B 0.78  0.09
A
Adiponectin (g/ml) 6.4  0.5
A 7.8  0.7
A 8.3  0.7
B
Plasma lipid homeostasis
Total cholesterol (mmol/l) 4.54  0.16
A 4.23  0.16
A 4.34  0.15
A
Triglycerides (mmol/l) 1.57  0.19
A 1.54  0.17
A 1.48  0.17
A
HDL cholesterol (mmol/l) 1.22  0.05
A 1.17  0.06
A 1.30  0.06
B
Inﬂammatory markers
Plasma hs-CRP (mg/dl) 3.1  0.8
A 2.5  0.9
B 2.7  0.8
B
Plasma IL-6 (pg/ml) 4.4  0.4
A 4.2  0.4
A 3.4  0.4
A
Plasma orosomucoid (g/l) 1.02  0.04
A,B 0.94  0.04
A 0.86  0.03
B
Values are expressed as mean  SE (n 	 30). Fat mass %, fat-free mass %: values expressed as a percentage of body weight. Paired Wilcoxon
stands for analyzing parameters changes between various time points. Data not sharing the same letter within a horizontal line are
signiﬁcantly different (P  0.05). REE: resting energy expenditure.
J.-P. FURET AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, DECEMBER 2010 3051lower in OB/D subjects before RYGB, increased at M3 and
remained stable at M6 (supplementary Table 3). The
populations of Clostridium (C. leptum and C. coccoides)
were stable post-RYGB.
Association between microbiota composition and
clinical phenotypes before RYGB. In OB/nD and OB/D
subjects, we observed signiﬁcant relationships between
the amount of F. prausnitzii, E. coli, and Bacteroides/
Prevotella and metabolic and inﬂammatory parameters
(supplementary Table 4A). The strongest associations
were found for the amount of F. prausnitzii, which was
negatively correlated with serum concentrations of inﬂam-
matory circulating markers (hs-CRP Rs 0.54, P  0.01
and IL-6 Rs 0.65, P  0.001). This negative correlation
was consistently signiﬁcant when analyzed alone in the
OB/nD subjects. No signiﬁcant association was correlated
with age for any analysis.
Time-dependant associations between metabolic
phenotypes and bacterial populations. Statistical LME
models were used to distinguish within-subject from be-
tween-subject sources of variation and to describe how
trajectories in clinical and bacterial population mean
responses showed related changes over time. Analyses
ﬁrstly included the entire population of obese subjects
regardless of their diabetic status, and secondly in the
OB/nD group or the OB/D group alone. The corpulence
parameters, including body weight, BMI, body fat mass,
and serum leptin concentrations, were correlated nega-
tively with the counts of Bacteroides/Prevotella and E.
coli, while positively with the amounts of Biﬁdobacterium
population, independent of the diabetic states.
In the OB/nD group, Bacteroides/Prevotella counts cor-
related negatively with calorie intake (P  0.01), which
drastically changed after the bypass (supplementary Table
4B). Analysis, performed in the OB/nD group and associ-
ating calorie intake and each of the adiposity-related
parameters as ﬁxed-effects in a combined LME model,
conﬁrmed the negative relationship between Bacteroides/
Prevotella counts and the decrease in food consumption
post-RYGB (P  0.05). This result was independent of
corpulence. The combined model could not demonstrate
signiﬁcant independent relationships with any of the adi-
posity-related parameters, thus indicating that variations
in Bacteroides/Prevotella population after surgery are re-
lated mostly to calorie intake in this cohort.
Unlike the Bacteroides/Prevotella population, the rela-
tionship between calorie intake and E. coli counts lost
statistical signiﬁcance in the combined model. This sug-
gests that E. coli could be considered as a marker of
corpulence variation after surgery, independent of energy
intake. The relationships between the microbiota and
these clinical parameters, explored through PCA, is illus-
trated in Fig. 2A, which displays the strong negative
correlation between E. coli counts and leptin serum
concentration (Rs 0.53, P  0.001). This correlation is
reinforced in Fig. 2B, which concomitantly illustrates the
kinetic evolution between E. coli population and leptin as
a mirror image.
Time-dependant associations between inﬂammatory
parameters and changes in bacterial populations:
importance of F. prausnitzii. F. prausnitzii showed a
consistent correlation with low-grade inﬂammation. After
the surgery, the circulating inﬂammatory parameters (hs-
CRP, IL-6, and orosomucoid) were reduced and an asso-
ciation was found with an increase in F. prausnitzii. F.
prausnitzii variation was strongly and negatively corre-
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serum levels when nondiabetic and diabetic obese sub-
jects were grouped together. The correlations with hs-CRP
and IL-6 were maintained in the OB/nD group (supplemen-
tary Table 4B). These relationships were independent of
calorie intake.
DISCUSSION
Analysis of the dynamic changes post-RYGB provided
important information regarding potential associations
between gut microbiota composition, food intake, meta-
bolic adaptations, and inﬂammation. In spite of the rela-
tively sample size of the diabetic group and some
incompletion in the collection of fecal samples, this study
compared not only the different proﬁle of gut microbiota
between lean and obese diabetic or nondiabetic subjects,
but revealed for the ﬁrst time that changes of gut micro-
biota in the same individual before and after RYGB asso-
ciate with a series of phenotypes. While some gut bacteria
groups correlated with energy intake, body corpulence,
and metabolic changes, others, such as F. prausnitzii,
associated with changes in the inﬂammatory state and
diabetes.
Our observation was made in severely obese subjects
and might not be extended to moderately obese subjects.
However, the lower proportion of Bacteroides/Prevotella
in obese subjects before RYGB and their increase after
weight loss are in agreement with landmark studies in less
obese populations (11,20). Correlation studies in LME
kinetic models provide important information showing
that these populations of bacteria were strongly associ-
ated with body composition and metabolic parameters.
After RYGB, the higher the increase in the proportions
of Bacteroides/Prevotella, the better the reduction in
body fat mass and plasma leptin. These associations
were dependent on energy intake. The estimated Firmi-
cutes-to-Bacteroidetes ratio diminished substantially
during weight loss, an observation also made in our
study mostly due to the increase in Bacteroides/Pre-
votella. A degree of controversy was raised with regard
to this result. No changes in the proportion of Bacte-
roidetes or Firmicutes-to-Bacteroidetes ratio were
found, while the total numbers of bacteria decreased in
other studies (12,21). These discrepancies could be
attributed to substantial differences in clinical protocols
with varying levels and duration of calorie restriction
and fat mass loss. RYGB could be considered as a
unique model that can be clinically followed over time
in the same individual. RYGB was found to be associ-
ated with a decrease in Firmicutes together with an
increase in 
-Proteobacteria in three adults (22). In this
ﬁrst study, the individual fecal samples before and after
weight loss were not paired, and no information was
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FIG. 1. Quantiﬁcations of fecal microbiota in lean control subjects and obese subjects
before (M0) and after surgery (M3 and M6). The qPCR results were plotted as boxes and
whiskers graph. The boxes (containing 50% of all values) show the median (horizontal line
across the middle of the box) and interquartile range, while the whiskers represent the 10th
and 90th percentiles. The extreme data points are indicated as circles. Data not sharing the
same letter in parentheses within a horizontal line are signiﬁcantly different (P < 0.05).
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phenotypic changes.
Here our patients were followed for 6 months with a
marked reduction in food intake at M3 and M6 post-RYGB.
It is important to note that there is a well-known uncer-
tainty and possible underestimation of food intake in
obese subjects (23). Nevertheless, after a short fasting
period (1–3 days), the subjects started to increase their
food intake that was composed of liquid or semi-liquid
foods for 1 week. During the 3 months after RYGB,
starch-based foods are often the principal food items with
solid foods being progressively reintroduced. With re-
duced calorie intake and changes in body composition,
leptin dropped and its variations were negatively associ-
ated with the amount of Bacteroides/Prevotella and E.
coli, while positively associated with Biﬁdobacterium and
Lactobacillus/Leuconostoc/Pediococcus. Among its di-
verse physiological functions, the major adipocyte-se-
creted hormone, leptin, has a critical role in the initiation
of adaptation responses to starvation (24). In the present
study, leptin levels fell rapidly with the onset of energy
deprivation at M3 (50% of basal values) and relatively
stabilized at M6 while BMI, fat mass, and adipocyte sizes
continued to shrink, which is in line with the results found
in other studies (25). This phenomenon is recognized as
signaling the shift between sufﬁcient and insufﬁcient body
energy. The ability of sustained fasting to induce dissoci-
ation between circulating leptin levels and adipose tissue
mass could also reﬂect a permissive effect of insulin on
leptin secretion. This may have conferred a survival ad-
vantage during evolution as leptin stimulates energy ex-
penditure and inhibits appetite (26). In agreement with
Bajzer and Seeley (27), changes in gut microbiota post-
RYGB could be linked to maximizing energy harvest as a
host adaptation to the starvation-like condition. The fact
that for most gut bacteria, changes were observed at M3
and remained stable at M6 (supplementary Table 3) while
corpulence and metabolic factors continued to improve
favors this particular interpretation. This is also strength-
ened by the results of another study (L.-C. Kong, S.
Rizkalla, K. Cle ´ment, et al.) from our laboratory that
demonstrates early changes in fecal bacteria population,
which started 1 week after caloric restriction. Interest-
ingly, compared with germ-free animals, hepatic ketogen-
esis is enhanced during 24-h fasting in mice (CONV-D)
after a microbiota transplant from the distal gut of con-
ventionally raised lean counterparts fed with carbohy-
drates (28). The CONV-D mice showed an increase of
short-chain fatty acids, and the proportion of Bacte-
roidetes switched from 20.6% at the fed state to 42.3% at
the fasted state, while the proportion of Firmicutes re-
duced from 77.1 to 52.6%. We also found that the relation-
ship between some gut microbiota changes and
corpulence and metabolic parameters might not be statis-
tically dependent on dietary changes as in the case of E.
coli and Biﬁdobacterium. This is an indirect indication
that microbiota components could participate in meta-
bolic changes associated with this surgical procedure.
RYGB procedure per se may contribute to changes in
gut microbiota composition. RYGB creates a small gastric
pouch and the distal stomach and proximal small intestine
are bypassed by attaching the distal end of the mid-
jejunum to the proximal gastric pouch. The bile and
pancreatic limb is attached along the Roux limb. Gastric
acidity is bypassed leading to a reduction of chloride acid
ﬂux in the gut. Patients were also under the proton pump
inhibitor therapy during the ﬁrst 3 months, which can also
inﬂuence the gastric pH. The resulting increased pH,
together with the downstream delivery of bile acids, could
contribute to modify fecal bacteria population. In in vitro
culture studies, the growth of Bacteroidetes was found to
be inhibited when reducing pH, while the growth of E. coli
was facilitated by increased pH (29). We did not measure
the pH in our subjects’ fecal samples, but the decreased
acidity in the gut after RYGB could favor an increase in
Bacteroides/Prevotella and E. coli counts. The changes in
E. coli strongly correlated negatively with leptin variation
(Fig. 2A). However, leptin can also be secreted by cells in
the lower half of the stomach glands (30). The signaling
molecules mechanistically involved in driving these links
need to be elucidated. Another consequence of pH change
post-RYGB could be the decrease in Lactobacillus/Leu-
A
B
 Bifidobacterium  
 E. coli  
 BMI  
 Cell size  
 leptin 
 HOMA-IR 
 Orosomucoid  
 calorie intake  
 F . prausnitzii  
 Bacteroides / 
Prevotella  
E. coli 
- 6 
- 4 
- 2 
0 
A  B  B 
 M0        M3        M6 
0 
20 
40 
60 
80 
100 
A  B  B 
Leptin 
l
o
g
1
0
 
 
b
a
c
t
e
r
i
a
 
/
 
g
 
o
f
 
s
t
o
o
l
 
n
g
/
m
l
 
FIG. 2. Relationship between changes in fecal microbiota composition
and clinical parameters in obese patients following RYGB surgery.
Real-time qPCR quantiﬁcations were used to determine the fecal
microbiota composition for the bacterial groups indicated in supple-
mentary Table 6. Clinical parameters included adipocyte cell size, BMI,
calorie intake, HOMA-IR, leptin, and orosomucoid. A: Principal compo-
nent analysis (between class analyses). Bold arrows indicate the
marked inverse relationship between changes in E. coli population and
leptin serum concentrations. B: Dynamics of E. coli population evolu-
tion and leptin concentration during the study. E. coli population
levels are expressed as mean  SEM of the log10 value of normalized
data calculated as the log number of targeted bacteria minus the log
number of all bacteria. Leptin results were expressed as mean  SEM
of serum concentrations.
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not consistent with the studies in mice that suggest a
beneﬁcial effect of Biﬁdobacterium species in the im-
provement of obesity-related metabolic and inﬂammatory
condition (8). The Biﬁdobacterium genus, however, is
complex. In adolescents losing moderate amounts of
weight, the counts of B. biﬁdum and of B. breve dimin-
ished while B. catenulatum increased (32). Information on
the intake of prebiotic or probiotic are not available in this
study; hence, we cannot exclude a possible inﬂuence of
functional ingredients included in foods (e.g., yogurts) on
these bacteria.
Shorter- and longer-term studies are needed to explore
the dynamics of subjects undergoing bypass surgery with
attention given to food intake behavior, measures of
metabolic mediators (such as short-chain fatty acids and
free fatty acids), measures of fecal pH to explore the
dependency between changes in food intake, the inﬂuence
of the surgery per se, and gut bacterial groups. A compar-
ison with patients only subjected to a restrictive surgical
procedure (i.e., gastroplasty) would be useful in this
respect.
The other important information provided here was that
F. prausnitzii was associated with inﬂammatory markers.
F. prausnitzii has been identiﬁed as a conserved and
dominant species of the human fecal microbiota of healthy
individuals (33). F. prausnitzii might play a role in
preventing local bowel inﬂammation and infection in acute
inﬂammatory disease. A reduction of F. prausnitzii has
been described in inﬂammatory bowel disease and in
infectious colitis (34). Our study suggests that F. prausnit-
zii could also play a role in low-grade inﬂammation
pathologies like obesity and diabetes (35–37). The rela-
tionship between F. prausnitzii and inﬂammatory mark-
ers was observed both in OB/nD and OB/D patients and
remained after adjustment for BMI. The proportions of F.
prausnitzii were lower in type 2 diabetic subjects display-
ing a worsening of their low-grade inﬂammation (38)
and higher insulin resistance. A negative association
was also seen between F. prausnitzii and HOMA-IR,
which could be explained by the amelioration of glucose
metabolism in the diabetic group. However in the
present study, this was not true for adiponectin, another
marker of insulin sensitivity. The discrepancy between
HOMA-IR and adiponectin during weight loss has been
well documented (39).
F. prausnitzii population variation was associated with
modulation of urinary metabolites of diverse structure
indicating that this species is a highly active member of the
microbiome, inﬂuencing host pathways (40). F. prausnit-
zii exhibits anti-inﬂammatory effects, partly due to se-
creted metabolites able to block nuclear factor-B
activation and the secretion of proinﬂammatory mediators
(41). Oral administration of F. prausnitzii or of superna-
tant from F. prausnitzii cultures increased the production
of IL-10 by blood mononuclear cells and reduced the
production of the proinﬂammatory mediator-like IL-12 in
the colon. The modulation of nuclear factor-B by phar-
macological agents such as statins or salicylates has been
proposed as a tool to improve insulin sensitivity in type 2
diabetic patients (42,43). Our study raises the question
regarding the role of F. prausnitzii as a mediator of
low-grade inﬂammation in obesity and diabetes and open
avenues for future investigation exploring its contribution
to insulin resistance.
Because of an increasing interest in treating type 2
diabetes with gastric bypass surgery, the improvement of
insulin sensitivity and the reduction of diabetes in subjects
postsurgery has become a primary axis of interest (44).
Unraveling the immediate and long-term adaptations asso-
ciated with gastric bypass surgery has proved challenging
predominantly because the consequences of this proce-
dure include caloric restriction, diminished nutrient ab-
sorption, reduced adipose mass, modiﬁed gut hormone
signaling, and changes in whole-body glucose metabolism,
which can each cause numerous physiological and meta-
bolic adaptations (45,46). Hypotheses have been postu-
lated to explain the improved insulin sensitivity witnessed
postsurgery and include the altered secretion of gut hor-
mones (47,48), modiﬁcations in intestinal gluconeogenesis
(49), and changes in intramyocellular lipid content (50).
While the deﬁnitive explanation for improved insulin
sensitivity post-RYGB remains unclear, it is most prob-
ably a combination of the aforementioned hypotheses.
Components of gut microbiota and possibly the relation-
ship between gut hormones and F. prausnitzii should
also be considered in this context. Taken together, the
applicability of F. prausnitzii as a valuable therapeutic
tool for the improvement of inﬂammation, blood glu-
cose tolerance, and insulin sensitivity, calls for more
investigations.
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